AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00510510
Drug: NVA237 200 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder inhalation once a day for up to 28 days
Trial: NCT04426409
Drug: tarivid ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaseline ointment is applied to both noses.
Trial: NCT01369277
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administration of matching placebo in tablet formulation at the fasted state
Trial: NCT03424291
Drug: Apatinib plus chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 500 mg qd po Taxus + platinum or 5FU + platinum (drug dose reference to clinical) palliative radiotherapy dose ≥ 40Gy and radical radiotherapy dose (60-70Gy)
Trial: NCT02101567
Drug: Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute after delivery of the head in cesarean section.
Trial: NCT03529331
Drug: Hydrocodone/Acetaminophen
RxNorm normalized name: hydrocodone/acetaminophen 5 mg-500 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days
Trial: NCT01482156
Drug: RAD001 + BEZ235
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD001 is formulated as tablets of 2.5 mg and 5 mg strength, blistered in units of 10 tablets (for oral use) each. Blisters should be opened only at the time of dministration as the drug is both hygroscopic and light-sensitive. RAD001 should be administered immediately after a meal with a large glass of water. BEZ235 is supplied as 50-mg, 200-mg, 300-mg and 400-mg sachets (for oral use). BEZ235 is packaged in aluminum foil bags. Bags are packaged in a box. Patients will receive RAD001 in combination with BEZ235.
Trial: NCT03894800
Drug: Fentanyl (F1)
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention fentanyl 0.025 mg i.v. and NaCl for inhalation will be administered(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
Trial: NCT03894800
Drug: Fentanyl (F2)
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention fentanyl 0.05 mg i.v. and NaCl for inhalation will be administered.(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
Trial: NCT00078793
Drug: Enbrel®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept alone, etanercept plus methotrexate or other DMARDs
Trial: NCT01125930
Drug: vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel that does not contain active drug. The gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use.
Trial: NCT02049203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00865605
Drug: Halobetasol Propionate 0.05% Ointment, single exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A: Other Subjects received Alpharma/Purepac USHP formulated products
Trial: NCT00865605
Drug: Ultravate® 0.05% ointment, single exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received Bristol-Myers Squibb Company formulated products
Trial: NCT00409825
Drug: 17-OHPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-muscular injection of 250 mg 17-OHPC administered weekly between the second and third trimesters of pregnancy, until time of delivery.
Trial: NCT01724268
Drug: Pred + Meth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PREDNISOLONE 10mg orally ONCE DAILY and Methotrexate 25 mg / day
Trial: NCT01724268
Drug: Anti TNF + Meth
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02995148
Drug: BAY987521
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-104)
Trial: NCT02995148
Drug: SPF Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Trial: NCT02650752
Drug: Lapatinib in Tandem With Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02687256
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04132713
Drug: Capecitabine 150Mg Oral Tablet
RxNorm normalized name: Capecitabine 150mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced breast cancer patients with first-line medication
Trial: NCT03942666
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet of CHF 6532
Trial: NCT03942666
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet of CHF 6532
Trial: NCT01478620
Drug: Canephron® N
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3x 2 coated tablets/day for 7 days p.o.
Trial: NCT01813656
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo group,5mg/pill,10mg/day non-forced titration method,last 12 weeks
Trial: NCT00564525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication taken for 4 weeks
Trial: NCT01045590
Drug: titration
RxNorm normalized name: Rebif Titration Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the glibenclamide plus placebo treatment group Patients in the glibenclamide plus placebo treatment group who have FPG \< 270mg/dL after the glibenclamide 5mg om run-in will continue to receive glibenclamide 5mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of \< 7%. If the HbA1c is \> 7%, the dose of glibenclamide will be escalated in the following sequence: from 5mg om, to 5mg om, 2.5mg on, to 5mg bd and 7.5mg om, 5mg on, to 7.5mg bd. The maximum total daily dose will not exceed 15 mg. A downward titration of glibenclamide using the above sequence in the reverse order can be used to maintain normoglycemia at any visit. Once the target HbA1c level of \< 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is \> 7% for 2 subsequent visits, the patient will be withdrawn from the study.
Trial: NCT01045590
Drug: titration
RxNorm normalized name: Rebif Titration Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the glibenclamide + rosiglitazone treatment group who have FPG \< 270mg/dL after the glibenclamide 5mg om run-in will receive glibenclamide 5mg om + rosiglitazone 4mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of \< 7%. If the HbA1c is \> 7%, the dose of glibenclamide will be escalated in a similar fashion as above. The only exception is at visit 5 when the dose of rosiglitazone is increased (see next paragraph). Once the target HbA1c level of \< 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is \> 7% for 2 subsequent visits, the patient will be withdrawn from the study.
Trial: NCT00099736
Drug: FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids
Trial: NCT00099736
Drug: FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids
Trial: NCT00099736
Drug: MMF 2 g + full-dose Neoral (FDN) + corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mycophenolate mofetil (MMF) + full-dose Neoral (FDN) + corticosteroids
Trial: NCT04130087
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Placebo Tablet, identical appearance to experimental tablet.
Trial: NCT00649870
Drug: Valtrex® Tablets 1000 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg, single dose fed
Trial: NCT00981240
Drug: SAR103168
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Concentrate for solution for infusion~Route of administration: Intravenous infusion
Trial: NCT00895232
Drug: Cohort II
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00895232
Drug: Cohort III
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02841709
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules for oral administration matching the ACT-541468 capsules
Trial: NCT04333706
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg BID
Trial: NCT02333370
Drug: LEE011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEE011 as 50 mg and 200 mg hard gelatin oral capsules as individual patient supply packaged in bottles. LEE011 will be taken QD - days 1-21 of each 28 days cycle.
Trial: NCT01929109
Drug: LY2409021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01418157
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily
Trial: NCT02690727
Drug: RP6530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT03105583
Drug: Medication use during pregnancy
RxNorm normalized name: PREGNANCY TEST
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03750565
Drug: TD-1473 - Dose A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule/tablet, QD
Trial: NCT03750565
Drug: TD-1473 - Dose B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule/tablet, QD
Trial: NCT03750565
Drug: TD-1473 - Dose C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule/tablet, QD
Trial: NCT03750565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule/tablet, QD
Trial: NCT01645384
Drug: Atorvastatin Calcium Tablets, 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
Trial: NCT01578174
Drug: Normal saline 0.9%
RxNorm normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 100mL(guess as 2㎍/mL):the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
Trial: NCT00783406
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00941928
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg once a day by vein on Days -5 and -4 over 2 hours.
Trial: NCT00089414
Drug: Ethinyl Estradiol/Drospirenone
RxNorm normalized name: ETHINYL ESTRADIOL/DROSPIRENONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug administered dependent upon arm.
Trial: NCT00089414
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00089414
Drug: CDB 2914
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02221830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This intervention utilizes a Placebo Camparator
Trial: NCT00232973
Drug: ICXP007
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00998699
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile solution subcutaneously administered every 4 weeks for 12 weeks
Trial: NCT02336737
Drug: Technetium Tc99m Sulfur Colloid
RxNorm normalized name: Kit for the Prepartion of Technetium Tc99m Sulfur Colloid KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of a single dose of radioisotope (Technetium Tc99m Sulfur Colloid)
Trial: NCT02899130
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive compound that is similar looking as the intervention
Trial: NCT00356200
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The sterile placebo (sesame oil with 1.2% (w/v) benzyl alcohol) was prepared at the University of Iowa, Division of Pharmaceutical Services, a FDA registered pharmaceutical manufacturing facility.
Trial: NCT02398188
Drug: LIPO-202
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02398188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02349061
Drug: Placebo Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenously at Week 0.
Trial: NCT02349061
Drug: Placebo SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneously at Weeks 8 and 16.
Trial: NCT00316719
Drug: LAM group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects took one LAM 100mg tablet orally once daily and one ADV placebo tablet orally once daily.
Trial: NCT00316719
Drug: ADV group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects took one ADV 10mg tablet orally once daily and one LAM placebo tablet orally once daily.
Trial: NCT01397162
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching fluticasone propionate HFA MDI
Trial: NCT00812253
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
Trial: NCT03989700
Drug: Thiamine Mononitrate
RxNorm normalized name: Thiamine Mononitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose group: thaimine mononitrate 25 mg/day per oral daily for 4 weeks High dose group: thaimine mononitrate 50 mg/day per oral daily for 4 weeks Placebo group: placebo 25 mg/day per oral daily for 4 weeks
Trial: NCT00541684
Drug: MK0954, /Duration of Treatment : 16 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03994107
Drug: Pegylated Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First phase PLD: 30mg/m2；35mg/m2；40mg/m2；IV, d1, q21d×6.~Second phase~PLD：MTD. IV, d1, q21d×6.
Trial: NCT04009616
Drug: Placebo mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rinsing with placebo mouthwash for 5 days.
Trial: NCT04330872
Drug: Plain Aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will be assigned to receive either Plain Aspirin and will be required to continue taking them throughout the study (three days).
Trial: NCT03403049
Drug: Gemcitabine + Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy.
Trial: NCT00255177
Drug: VGX-410 (Mifepristone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VGX-410 tablets taken daily or twice daily for 28 days
Trial: NCT00255177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for VGX-410 tablets taken daily or twice daily for 28 days
Trial: NCT03244774
Drug: POF
RxNorm normalized name: Ta-Poff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
Trial: NCT00055250
Drug: LY293111
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00055250
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02918162
Drug: Standard of care chemotherapy regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen containing at least a platinum and Fluorouracil (5-FU) agent (per National Comprehensive Cancer Network guidelines) - such as Doublet or Triplet chemotherapy with capecitabine, oxaliplatin, and epirubicin (optional) (21 day cycle). Epirubicin can be excluded at the discretion of the treating physician.~Example:~Oxaliplatin dosed IV at 130 mg/m2 every 21 days per cycle. Capecitabine dosed orally at 625mg/m2 twice a day daily.
Trial: NCT01443065
Drug: 5-fluoro-uracil
RxNorm normalized name: Fluoro Uracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
Trial: NCT01443065
Drug: AMG102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/kg over 60 mn every 2 weeks up to progression or toxicity
Trial: NCT02909140
Drug: Intracameral 0.2- 0.3ml of epinephrine 1:10,000
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00361322
Drug: clindamycin phosphate
RxNorm normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01384656
Drug: GIK solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive 0.3 ml/kg/hr GIK solution or the same volume of normal saline depending on the group during off-pump coronary bypass surgery. GIK solution consist of 50% glucose, potassium 80 mEq, and regular insulin 325 IU/500ml.
Trial: NCT00131508
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00128453
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00028665
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide IV over 3-6 hours on day 16.
Trial: NCT01462942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled dose-matched placebo, twice per day
Trial: NCT03978884
Drug: Losartan/Hydrochlorothiazide 50 Mg-12.5 Mg ORAL TABLET
RxNorm normalized name: losartan/hydrochlorothiazide 50 mg-12.5 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 1 tab daily
Trial: NCT03978884
Drug: Losartan/Hydrochlorothiazide 100 Mg-25 Mg ORAL TABLET
RxNorm normalized name: losartan/hydrochlorothiazide 100 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 1 tab daily
Trial: NCT01400113
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Sublingual Tablet, single-dose
Trial: NCT00453687
Drug: GSK233705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: investigational drug
Trial: NCT01650324
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
Trial: NCT00219258
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01915732
Drug: Duac™Once Daily Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide
Trial: NCT01915732
Drug: 1% clindamycin phosphate gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% clindamycin as clindamycin phosphate
Trial: NCT00602030
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching entinostat tablets on Days 1 and 15 of a 28-day cycle.
Trial: NCT02470832
Drug: RG1662
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03713892
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally administered
Trial: NCT01360593
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be taken orally twice daily on days 1-14 every 3 weeks for 4 cycles (12 weeks) prior to stereotactic radiosurgery as follows:~Capecitabine 650 mg/m2 twice daily for days 1-14 every 3 weeks for up to 4 cycles.
Trial: NCT01616732
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TU im
Trial: NCT01616732
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo im
Trial: NCT01730313
Drug: Pyridoxine
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01730313
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no